معرفی
Professor Roger Griffin is a faculty member at Newcastle University, specializing in kinase inhibitors and DNA repair mechanisms for cancer therapy. His research focuses on structure-based drug design and pharmacological profiling of inhibitors targeting pathways like MDM2-p53, ERK5, and CDK2.
- Key research areas: Kinase inhibition, DNA repair, anticancer drug development, protein-protein interactions, radiosensitization, and metabolic targeting in oncology.
Recent article trends highlight his work on irreversible inhibitors, oral bioavailability, and selective kinase targeting to enhance therapeutic outcomes. Publications from 2016–2022 emphasize ERK5/CDK2/MDM2 inhibition strategies and drug repurposing.
Collaborations include researchers like Dr. Celine Cano, Professor Nicola Curtin, and Emeritus Professor Bernard Golding. His work has been cited in studies on sulfatase inhibition, ATM kinase, and PARP inhibitors.